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Background: The immunosuppressive properties of HLA-G protein can create a tolerogenic environment that may
allow Plasmodium falciparum to avoid host immune responses. There are known associations between high levels
of circulating soluble HLA-G (sHLA-G) and either parasite or viral infections and it has been suggested that the
induction of sHLA-G expression could be a mechanism via which infectious agents subvert host immune defence.
The study presented here is the first to investigate the possible association between sHLA-G and malaria or malaria
related risk factors in Benin.
Methods: A parasitological and clinical follow-up of 165 mothers and their newborns from delivery through to one
year of age was conducted in the Tori Bossito area of southern Benin. Plasma levels of sHLA-G were determined by
ELISA in maternal peripheral and cord blood and again in infants' peripheral blood at 3, 6, 9 and 12 months of age.
The associations between the levels of sHLA-G and malaria risk factors were investigated through multivariate
mixed models.
Results: Strong correlations were observed between the maternal and cord plasma concentrations of sHLA-G. In
multivariate analyses, high cord plasma levels of sHLA-G were independently associated with (i) low birth weight
and (ii) an increased risk of P. falciparum infection in infancy.
Conclusion: These results show for the first time the possible involvement of sHLA-G in generating immune
tolerance during pregnancy-associated malaria. Soluble HLA-G may represent a useful marker of susceptibility to
malaria in infants and be associated with the higher susceptibility to infection observed for LBW children.
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Human Leucocyte Antigen-G (HLA-G) is a non-classical
HLA class I antigen that differs from other HLA class I
molecules by its limited polymorphism, its restricted tissue
distribution and the characteristics of its protein expres-
sion. Seven protein isoforms can be generated from* Correspondence: David.Courtin@ird.fr
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unless otherwise stated.alternative splicing, comprising four membrane-bound iso-
forms (HLA-G1, −G2, −G3, and -G4) and three soluble
isoforms (HLA-G5, −G6, and -G7). A soluble form
of HLA-G1 can be generated by proteolytic cleavage of
membrane-bound HLA-G1. The main isoforms present in
plasma are shed HLA-G1 and secreted HLA-G5 proteins.
HLA-G plays a crucial role in immune tolerance and
differs from HLA class I molecules in its negative immu-
noregulatory functions and its interactions with leukocyte
immunoglobulin-like inhibitory receptors ILT2 and ILT4
or killer cell immunoglobulin-like receptor (KIR2DL4)
that are expressed on a range of immune cells [1,2]. The
crucial role played by both membrane-bound and solubleal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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be beneficial or detrimental [1]. Secretion of sHLA-G by
the early conceptus appears to be essential for successful
implantation, and it has been used as a reliable marker of
an increased chance of successful pregnancy following
in vitro fertilization [3,4]. Moreover, HLA-G expression by
trophoblasts has been demonstrated to protect the fetus
from maternal immune rejection [5]. HLA-G is also asso-
ciated with progression of tumours [6,7] and viral infec-
tions [8,9]. To facilitate their spread in the host, some
viruses and parasites purportedly induce changes in the
level and distribution of HLA-G thereby suppressing the
function of various immune cells [10-13].
Plasmodium falciparum malaria is endemic especially
in the tropical areas, of Africa. Malaria due to P. falcip-
arum infection during pregnancy is associated with a
range of poor outcomes including low birth weight
[14,15]. Moreover children born to mothers with placen-
tal infection seem to be themselves more susceptible to
malaria during the first months of life [16-18]. This sus-
ceptibility has been related to disturbances of immune
development in utero leading to immune tolerance [19].
In the context of pregnancy-associated malaria, it has
been reported that the percentage of trophoblasts express-
ing membrane-bound HLA-G was lower in placentas
infected with P. falciparum compared with uninfected pla-
centas, suggesting that HLA-G down-regulation may be
involved in the poor birth outcomes associated with P. fal-
ciparum infection [20]. The levels of sHLA-G in biological
fluids were not quantified in that study.
Possible associations between malaria and sHLA-G
have not been explored to date. Here, the immunosup-
pressive properties of sHLA-G might contribute to an
individual's susceptibility to malaria and this study inves-




This cohort study was conducted in Tori Bossito area,
located 40 km north-east of Cotonou in southern Benin,
from June 2007 to January 2010, evaluating the determi-
nants of malaria incidence in the first months of life.
Women (n = 620) were enrolled at delivery and their in-
fants were actively followed-up during the first year of
life. Among them, 165 infants were selected according
to the placental malaria status of the mother and to the
availability of plasma for sHLA-G quantification at deliv-
ery (maternal and cord blood), and at 3, 6, 9 and 12
months. One group comprised all the mother/infant
pairs associated with an infected placenta (n = 51), whilst
a second group comprised 114 mother-infant pairs se-
lected randomly amongst infants born to mothers with
uninfected placentas. Details of the follow-up procedureshave been published elsewhere [18]. They are summa-
rized in the following section.
Data collection
At delivery, a questionnaire was conducted to gather in-
formation on women’s characteristics and on the course
of their current pregnancy. After delivery, thick and thin
placental blood smears were examined to detect placen-
tal infection defined by the presence of asexual forms of
P. falciparum. Smears were read by two technicians and
in case of discordance a third reading was performed by
a senior biologist.
At birth, newborn’s weight and length were measured
by midwives and gestational age was estimated using the
Ballard method [21]. During the follow-up of infants,
axillary temperature was measured weekly with a digital
thermometer by community health workers. In case of
temperature higher than 37.5°C, mothers were told to
bring their children to the health centre where a ques-
tionnaire was filled out. A rapid diagnostic test (RDT)
for malaria was performed and a thick blood smear
(TBS) made. TBSs were read by two laboratory techni-
cians (less than 1% disagreement). Symptomatic malaria
cases, defined as fever (>37.5°C) with TBS and/or RDT
positive, were treated with an artemisinin-based com-
bination therapy as recommended by the Benin National
Malaria Control Programme. Mothers were invited to
bring their infants to the health centre at any time for free
care in case of fever or clinical signs, and the same proto-
col was applied. Systematically, TBS were made every
month to detect asymptomatic infections. Every three
months, venous blood was sampled to quantify the level
of sHLA-G. Finally, the environmental risk of exposure to
malaria was modelled for each child, derived from a statis-
tical predictive model based on climatic, entomological
parameters, and characteristics of children’s immediate
surroundings as reported by Cottrell et al. [22].
Soluble HLA-G Quantification
Soluble HLA-G concentrations were evaluated by a spe-
cific sandwich ELISA in plasma using MEM-G/9 [23] and
anti-human β2-microglobulin as capture and detection
antibodies respectively [24]. Microtitration plates (Corning
Incorporated, USA) were coated overnight at 4°C with
10 μg/mL MEM-G/9 Mouse-anti-human HLA-G mAb
(ExbioPraha, Czech Republic). Plates were saturated
using 300 μl diluent buffer (DAKO, USA) ready to use
for 2 h. All samples were previously centrifuged and pre-
diluted (½) in diluent buffer. Plasma samples were tested
in duplicate and incubated for 2 h. Plates were incubated
for 1 h more with detection antibody (Rabbit-anti-human
β2-microglobulin: (DAKO, USA)). Then the plates were
incubated for 1 h with envision buffer (DAKO, USA)
to obtain anti-β2-microglobulin horseradish peroxidase
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All incubation steps were performed at room temperature
and followed by four washes using washing buffer (H2O,
PBS 1X, 0.1% Tween 20). The plates were incubated for
30 min with the substrate (Tetramethylbenzidine (TMB),
Sigma Aldrich, USA) and absorbance was measured at
490 nm after adding HCL (1 N). Total sHLA-G levels
were determined from a five-point standard curve (12.5-
200 ng/ml) using dilutions of calibrated HLA-G5 purified
from M8-HLA-G5 cell line culture supernatant and re-
sults were expressed as ng/mL.
Statistical analysis
Due to the skewed distribution of values, a logarithmic
transformation was applied to sHLA-G levels. All subse-
quent analyses were performed using the log trans-
formed sHLA-G level, defined as sHLA-G variable.
Univariate and multivariate analyses were performed to
identify the different factors associated with the sHLA-G
levels in maternal peripheral and cord blood.
The relationships between the levels of sHLA-G at a
given quarterly visit and the occurrence of malaria epi-
sodes in the previous trimester were determined. For this
first objective, the relationship between the dependent
variable (sHLAG) and the number of malaria episodes
during the previous trimester was analysed using a linear
mixed model.
The study was also interested in determining whether
the level of sHLA-G at a quarterly measurement was as-
sociated with the risk of developing malaria during the
following trimester. For this second objective, the relation-
ship between the number of infections at each trimester
(dependent variable) and the sHLAG level at the corre-
sponding quarterly visit was studied through a Poisson
mixed model. The sHLA-G level was used quantitatively
or categorized into four classes according to the quartiles,
and then adjacent classes were grouped if they showed
similar results in the final regression model.
All analyses were adjusted on maternal and newborn’s
covariates: The maternal covariates were: age (years),
placental malaria infection, gravidity, administration of
intermittent preventive treatment against malaria in preg-
nancy (IPTp), ethnicity group and village of residence.
The newborn covariates were: age (months), birth weight
(low birth weight (LBW) if <2500 g), gender, prematurity,
malaria episodes by trimester, and environmental risk of
exposure to malaria (RE).
All variables with p value below 0.20 in univariate
analysis were initially introduced into the multivariate
model. The final multivariate model was selected through
a backward procedure, and only covariates with a p-value
below 0.05 were kept. Malaria episodes (when treated as
the explanatory variable in the first approach), sHLA-G
(when treated as the explanatory variable in the secondapproach), placental malaria and environmental risk of ex-
position to malaria were forced in the final models. All
analyses were performed using Stata v.11.
Ethics
The study protocol was approved by the University of
Abomey-Calavi’s institutional review board and the IRD’s
Consultative Ethics Committee. All women signed in-
formed consent before enrolment and were able to with-
draw their consent at any time.
Results
Characteristics of study participant
The mean age of mothers was 26.5 years (SD = 6.3; range:
16–49); 19.7% were primigravidae and 86.2% declared
having received an intermittent preventive treatment (at
least one dose of sulphadoxine-pyrimethamine); 51 had an
infected placenta at delivery. Newborn’s mean birth weight
was 3001.4 g (SD = 413.9; range = 2147.5-4370.0), and
7.8% of them had a low birth weight (<2,500 g) (Table 1).
The total number of P. falciparum infections before 12
months was 143 (range =1-4 infections/newborn) with
109 symptomatic infections (with fever). For 22 of the in-
fants no parasites were detected at any time during the 12
months of follow-up.
Soluble HLA-G was detectable in 78.2% of the mater-
nal plasma samples (129/165) at delivery. Overall, the
average level of sHLA-G in maternal blood was 19.2 ng/
mL (SD =25.6, range = 0-132.2). In the 129 mothers with
detectable levels of sHLA-G at delivery, the mean level
was 24.4 ng/mL (SD = 26.5, range = 0.11-132.2). At birth,
the average level of sHLA-G in cord blood was 16.3 ng/mL
(SD = 26.8, range = 0-128.5) and 60.0% of children
(99/165) had detectable sHLA-G (27.0 ng/mL (SD= 30.0,
range = 0.75-128.5). Levels of sHLA-G were highly cor-
related (r = 0.74; p = 10−3) in maternal and cord blood
samples. The mean level in the maternal blood (19.2 ±
25.6 ng/mL) was significantly higher than in the cord
blood (16.3 ± 26.8 ng/mL) (Student paired test; p = 10−4).
In the first year of life the mean level of sHLA-G in
infants varied over time (Figure 1). This level decreased
from birth to three months, then increased until nine
months before stabilizing until twelve months.
Soluble HLA-G in maternal blood at delivery
Univariate analyses showed sHLA-G level in mother’s
blood to be significantly positively associated (p < 10−3)
with the level in cord blood, whereas IPTp was associated
with a lower level (p = 0.014). Ethnic group (p = 0.10) was
included in multivariate analysis. Although non-significant,
placental malaria infection (p = 0.39) was forced in multi-
variate analyses. Multivariate analysis confirmed these as-
sociations, except that belonging to “other ethnic groups”
became significantly associated with a higher level of
Table 1 Characteristics of mothers and infants included in
the study
MOTHERS (165)* Variables Characteristics
Age (years) Mean: 26.5 (+/−6.3)
Range: 16 – 49
Gravidity Primigravidity: 19.74% (30)
Mutligravidity: 80.26% (122)
Ethnicity Tori: 35.33% (98)
Fon: 10.00% (15)
Others**: 24.67% (37)

















Birth weight (grams) Mean: 3001.4 (+/−413.9)





Sex (Female/male) Female: 53.33% (88)
Male: 46.67% (77)
Prematurity Yes: 12.42% (19)
No: 87.58% (134)
sHLA-G in blood cord Detectable: 60.37% (99)
Undetectable: 39.63% (65)
*All the mothers included in the study were HIV negative; **Different ethnicity
groups were considered in the area study: Tori, Fon (majority ethnicity groups)
and Aïzo, Yoruba (minority ethnicity groups); ***IPTp: Intermittent Preventive
Treatment (sulphadoxine-pyrimethamine): treatment recommended by the
Benin National Malaria Control Program during pregnancy; ****Nine villages
































Figure 1 Mean levels of sHLA-G from birth (cord blood) to one
year old (3, 6, 9, 12 months).
Table 2 Factors associated with the levels of sHLA-G in
maternal blood at delivery using linear multivariate
regression
Covariates Estimation 95% CI p-value
Ethnicity group Tori (n = 94)
Fon (n = 15) 0.13 −0.57; 0.84 0.70 0.035
Other groups
(n = 35)
0.66 0.16; 1.15 0.01
IPTp No (n = 21)





0.37 0.24; 0.50 <10−3
Estimation represents regression coefficients which can be positive or
negative. Regression coefficients measure the increase (positive value) or
decrease (negative value) of the dependent variable (level of sHLA-G in
maternal blood at delivery) due to the presence of the independent ones.
Covariates included in linear multivariate regression were ethnicity group,
Intermittent Preventive Treatment, sHLA-G quantification in cord blood and
placental infection. Information concerning the four covariates was available
for 144 mothers. Covariates with significant p values were presented in
the Table 2.
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remained non-significant (Table 2).
Soluble HLA-G in cord blood at birth
In univariate analyses, high levels of sHLA-G in maternal
blood (p < 10−3) and LBW (p = 0.02) were significantly as-
sociated with a higher level of sHLA-G in cord blood. This
was confirmed by multivariate analysis, whereas placental
malaria infection was not related to sHLA-G in cord
blood (Table 3).Soluble HLA-G during the first year of life and malaria
infection
Univariate analyses showed that sHLA-G in infants' blood
during the follow-up was significantly associated with age
(p < 10−3), with the village of residence (p = 0.035), and
with a high level of sHLA-G both in maternal (p < 10−3)
and in cord blood (p < 10−3). LBW was also associated
with a high level of sHLA-G both in cord (p = 0.04) and in
peripheral blood during the first year of life (p = 0.004).
Malaria infections occurring during the trimester pre-
ceding blood samples and placental malaria infection
were not related to sHLA-G. In the multivariate linear
mixed model, age, LBW, environmental risk of malaria
and sHLA-G in cord blood were significantly associated
with a high level of sHLA-G (Table 4).
Table 3 Factors associated with the level of sHLA-G in
cord blood at birth using linear multivariate regression
Covariates Estimation 95% CI p-value
HLA-G in maternal
blood
No (n = 32)
Yes (n = 120) 1.23 0.72; 1.90 <10−3
Low birth weight No (n = 140)
Yes (n = 12) 0.73 0.04; 1.83 0.040
Estimation represents regression coefficients which can be positive or
negative. Regression coefficients measure the increase (positive value) or
decrease (negative value) of the dependent variable (level of sHLA-G in cord
blood at birth) due to the presence of independent ones. Covariates included
in linear multivariate regression were sHLA-G quantification in maternal blood,
low birth weight and placental infection. Information concerning the three
covariates was available for 152 infants. Covariates with significant p values
were presented in the Table 3.
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HLA-G in cord blood and the risk of malaria infection.
The risk of malaria infection during the follow-up (1.158,
CI 95 [0.698 – 1.921]) did not vary significantly (P = 0.569)
between children with no detectable soluble HLA-G at
birth and others.
Secondly we explored the same association taking into
account the quarterly measurements of soluble HLA-G.
In univariate analyses, the Poisson mixed model showed
that a high environmental exposure to malaria (p = 10−3)
and age (p = 10−3) were significantly associated with an
increased risk of malaria. Moreover, a significant associ-
ation (p = 0.016) was detected between the level of sHLA-
G at a quarterly measurement and the appearance of mal-
aria in the following months. LBW and placental malaria
were not associated with an increased risk of malaria
during the first year of life. The multivariate analyses con-
firmed these results, although the sHLA-G variable be-





Very low ≤0.66 (n = 93)
Low]0.66-1.85] (n = 109)
Median]1.85-4.81] (n = 95)
High >4.81 (n = 100)
sHLA-G in cord blood Continuous (n = 397)
Low birth weight No (n = 369)
Yes (n = 28)
Age of infant (months) 3 (n = 100)
6 (n = 103)
9 (n = 100)
12 (n = 94)
Estimation represents regression coefficients which can be positive or negative. Reg
value) of the dependent variable (level of sHLA-G in peripheral blood in the first ye
linear multivariate mixed regression were environmental risk, sHLA-G quantification
trimester preceding blood draws and placental infection. Covariates with significantsHLA-G levels were strictly significantly related to an
increased risk of malaria during the following trimester
(p = 0.02) (Table 5).
Discussion
This study is the first to investigate the association of
soluble HLA-G and malaria in pregnant women and
newborns. Children born to a mother with an infected
placenta have an increased risk of malaria and/or para-
sitaemia during the first months of life [16-18,25,26] and
it has been conjectured that placental infection with P. fal-
ciparum may alter infants’ immunological responses and
be responsible for an immune tolerance phenomenon
[25]. A recent study showed that placental P. falciparum
infection was also a risk factor for non-malarial infections
in infancy [27] strengthening the hypothesis that immune
tolerance may be not specific to malaria but may be gener-
alized to involve multiple pathogens. Among the proteins
that may be involved in a phenomenon of immune toler-
ance, sHLA-G could play a crucial role since it has been
described as one of the factors most relevant to the im-
mune tolerance present in several domains including
organ transplantation and cancer, but also infectious
diseases [1]. The principal results of the present study
showed that (i) high level of sHLA-G in infants in-
creased the risk of malaria, (ii) high levels of sHLA-G in
cord blood was associated with low birth weight, (iii)
sHLA-G levels in maternal peripheral blood at delivery
were highly correlated with sHLA-G in cord blood.
HLA-G modulates host immune response via interac-
tions with its inhibitory receptors that are expressed on
the surface of NK cells, T and B lymphocytes, monocytes,
dendritic cells and neutrophils, and could thus play a role
in susceptibility to infectious diseases. To date, only threel blood in the first year of life using linear multivariate
stimation 95% CI p-value
0.41 0.13; 0.70 0.005
0.32 0.03; 0.61 0.032 0.032
0.36 0.04; 0.67 0.026
1.13 0.73; 1.53 <10−3
1.03 0.31; 1.75 0.005
0.30 0.04; 0.56 0.023
0.76 0.49; 1.03 <10−3 <10−3
0.79 0.52; 1.07 <10−3
ression coefficients measure the increase (positive value) or decrease (negative
ar of life) due to the presence of independent ones. Covariates included in
in cord blood, Low birth weight, age, malaria infection occurring during the
p values were presented in the Table 4.
Table 5 Factors associated to the number of malaria infections in the first year of life, Tori-Bossito, 2007–2010:
multivariate mixed regression of Poisson
Covariates Incidence ratio 95% IC p-value
Environmental risk Low ≤0.66 (n = 114) 1
Median]0.66-4.81] (n = 219) 2.14 1.15; 3.98 0.016 <10−3
High >4.81 (n = 96) 6.89 3.50; 13.57 <10−3
sHLA-G level in peripheral blood of infant Null (n = 217) 1
Low (n = 170) 1.07 0.65; 1.77 0.775 0.06
High (n = 42) 2.29 1.12; 4.66 0.022
Age of infant (month) 3 (n = 139)
6 (n = 95) 2.26 1.19; 4.27 0.012 <10−3
9 (n = 99) 4.06 2.27; 7.28 <10−3
12 (n = 96) 2.76 1.56; 4.89 <10−3
Covariates included in multivariate mixed regression of Poisson were environmental risk, sHLA-G quantification in peripheral blood of infant, age, and placental
infection. Covariates with significant p values were presented in the Table 5.
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and malaria. The first of them suggested that HLA-G
down-regulation in P. falciparum-infected placentas may
be involved in poor birth outcomes [20]. Two recent re-
ports showed that genetic polymorphisms in HLA-G
3’UTR could influence the clinical and immunological re-
sponses directed to P. falciparum [28,29]. In the present
study, high levels of sHLA-G were associated with a sig-
nificant high incidence ratio of malaria. High expression
of sHLA-G observed in infants during the follow-up could
affect immune responses directed to P. falciparum, and in
particular the IgG1 and IgG3 antibody subclasses involved
in anti-malarial protection [30-32]. In agreement, a recent
study shows that soluble HLA-G impairs B cell responses
[2]. These results strongly suggest that the inhibition of
immune responses by HLA-G expression could lead to a
greater susceptibility to malaria infection.
Previous studies showed an association between high
levels of sHLA-G and parasitic or viral infections
[11,12,33]. It has been suggested that induction of sHLA-G
expression could help infectious agents to subvert host im-
mune defenses [8,9]. In this study, significant effect of P.
falciparum infection on sHLA-G levels was not observed.
However, as shown previously, other infections (viruses,
parasites) but also other cellular stresses (hypoxia…) can
be associated with different levels of sHLA-G. Since these
factors have not been taken into account in the follow-up,
the effect of malaria alone was too small to be detectable
and the possibility that some infections went undetected
despite close monitoring cannot be excluded. Moreover
this study showed that the intake of antimalarial preventive
treatment during pregnancy was correlated with decreased
levels of sHLA-G at delivery and that an increased expos-
ure to malaria (environmental risk) was associated with
higher levels of sHLA-G. Both these results suggest indir-
ectly that malaria could be related to the levels of sHLA-G.However, a lack of statistical power due to low number of
samples cannot be excluded in this preliminary study. In
the present study, higher levels of sHLA-G in cord blood
were associated with low birth weight, which itself is highly
related to infant morbidity and mortality [34]. It was sug-
gested that both HLA-G expression and genetic poly-
morphism of HLA-G may influence foetoplacental growth
[35]. The preceding results and the observations in this
study could be consistent with the involvement of HLA-G
in the higher risk of infectious morbidity to which LBW
babies are subjected. This is strengthened by the fact that
in study population, placental malaria was associated with
LBW [18], a higher risk of malaria but also a higher risk of
non-malarial infections during the first months of life
[36,37]. Put together these results seem to indicate that
placental infection could be considered as an indirect
marker of the complex phenomenon of immune tolerance
which may be not specific to malaria.
The plasma levels of sHLA-G in the peripheral blood
of the mother at delivery and in the cord blood were
highly correlated (r = 0.74; p = 10−3) as already reported
[38]. Although maternal IgG are actively transported
across the placenta, providing partial humoral protection
to the foetus, no data exists on the potential for transfer of
sHLA-G across the placental barrier. HLA-G molecules
are known to be expressed at the fetal–maternal interface
on the surface of cytotrophoblast cells, endothelial cells
and in amniotic fluid there by explaining the presence of
sHLA-G in cord blood [39,40]. This HLA-G expression is
known to inhibit maternal immune cells and to protect
the fetus from maternal rejection [5]. The expression of
sHLA-G in maternal blood is expected to come at least
from peripheral blood monocytes known to secrete HLA-
G upon various stimulations (cytokines, stress proteins,
hormones [1]…). More studies will be needed to address
the factors influencing sHLA-G expression in the mother
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HLA-G polymorphism influences sHLA-G plasma level in
Brazilian and French populations [41].
In conclusion, this work had shown an association
between high levels of sHLA-G and an increased risk of
malaria, and of low birth weight. These results suggest
that HLA-G could be associated not only with malaria
susceptibility during the first months of life but also with
the higher burden of infections low birth weight babies
are faced with. Further studies are ongoing including the
follow-up of pregnant women and their newborns and the
detection of both malarial and non-malarial infections.
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